Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR) - Total Liabilities
Based on the latest financial reports, Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR) has total liabilities worth TL661.10 Million TRY (≈ $14.81 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore MEDTR cash generation efficiency to assess how effectively this company generates cash.
Meditera Tibbi Malzeme Sanayi ve Ticaret AS - Total Liabilities Trend (2018–2025)
This chart illustrates how Meditera Tibbi Malzeme Sanayi ve Ticaret AS's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Meditera Tibbi Malzeme Sanayi ve Ticaret to evaluate the company's liquid asset resilience ratio.
Meditera Tibbi Malzeme Sanayi ve Ticaret AS Competitors by Total Liabilities
The table below lists competitors of Meditera Tibbi Malzeme Sanayi ve Ticaret AS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Stillwater Critical Minerals Corp
V:PGE
|
Canada | CA$2.18 Million |
|
Patriot One Technologies Inc
F:0PL
|
Germany | €10.94 Million |
|
Evermore Chemical Industry Co Ltd
TW:1735
|
Taiwan | NT$1.65 Billion |
|
Clipan Finance Indonesia Tbk
JK:CFIN
|
Indonesia | Rp4.04 Trillion |
|
Done.ai Group AB
ST:DONE
|
Sweden | Skr297.70 Million |
|
Global View Co Ltd
TW:3040
|
Taiwan | NT$574.45 Million |
|
Sea Oil Public Company Limited
BK:SEAOIL
|
Thailand | ฿1.64 Billion |
|
Future Vision II Acquisition Corporation Ordinary shares
NASDAQ:FVN
|
USA | $202.33K |
Liability Composition Analysis (2018–2025)
This chart breaks down Meditera Tibbi Malzeme Sanayi ve Ticaret AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Meditera Tibbi Malzeme Sanayi ve Ticaret.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Meditera Tibbi Malzeme Sanayi ve Ticaret AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Meditera Tibbi Malzeme Sanayi ve Ticaret AS (2018–2025)
The table below shows the annual total liabilities of Meditera Tibbi Malzeme Sanayi ve Ticaret AS from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | TL661.10 Million ≈ $14.81 Million |
-12.18% |
| 2024-12-31 | TL752.75 Million ≈ $16.86 Million |
+26.19% |
| 2023-12-31 | TL596.54 Million ≈ $13.36 Million |
+180.84% |
| 2022-12-31 | TL212.41 Million ≈ $4.76 Million |
+41.76% |
| 2021-12-31 | TL149.84 Million ≈ $3.36 Million |
+20.32% |
| 2020-12-31 | TL124.53 Million ≈ $2.79 Million |
+32.87% |
| 2019-12-31 | TL93.72 Million ≈ $2.10 Million |
-1.71% |
| 2018-12-31 | TL95.36 Million ≈ $2.14 Million |
-- |
About Meditera Tibbi Malzeme Sanayi ve Ticaret AS
Meditera Tibbi Malzeme Sanayi ve Ticaret Anonim Sirketi manufactures and sells medical devices in Turkey. The company offers two-way and single-line Infusion Systems; Chemotherapy Preparation and Administration Systems, such as medoconco automated drug preparation, diana semi-automatic drug dispensing, and ICU medical chemotherapy drug delivery systems; and respiratory systems products, includin… Read more